WO1991011206A1 - Alginate materials - Google Patents
Alginate materials Download PDFInfo
- Publication number
- WO1991011206A1 WO1991011206A1 PCT/GB1991/000119 GB9100119W WO9111206A1 WO 1991011206 A1 WO1991011206 A1 WO 1991011206A1 GB 9100119 W GB9100119 W GB 9100119W WO 9111206 A1 WO9111206 A1 WO 9111206A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alginate
- cation
- alginate material
- cations
- membrane
- Prior art date
Links
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 42
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 42
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229940072056 alginate Drugs 0.000 title claims abstract description 40
- 239000000463 material Substances 0.000 title claims abstract description 34
- 150000001768 cations Chemical class 0.000 claims abstract description 27
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims abstract description 6
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011575 calcium Substances 0.000 claims abstract description 4
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 4
- 229910052709 silver Inorganic materials 0.000 claims abstract description 4
- 239000004332 silver Substances 0.000 claims abstract description 4
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 4
- 239000011701 zinc Substances 0.000 claims abstract description 4
- 229910052684 Cerium Inorganic materials 0.000 claims abstract description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 3
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000010941 cobalt Substances 0.000 claims abstract description 3
- 229910017052 cobalt Inorganic materials 0.000 claims abstract description 3
- 229910052802 copper Inorganic materials 0.000 claims abstract description 3
- 239000010949 copper Substances 0.000 claims abstract description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims abstract description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000012528 membrane Substances 0.000 claims description 11
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 206010052428 Wound Diseases 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 239000002657 fibrous material Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- -1 cobalt cations Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the present invention relates alginate materials which are useful particularly (but not exclusively) for wound dressings.
- alginate materials have haemostatic and wound healing properties and may be used in various types of wound dressing * (see for example EP-A- 0 236 104 (Courtauld ⁇ ) ) .
- alginates for wound dressings are prepared by spinning a solution of sodium alginate into a ' bath containing calcium ions (usually provided by calcium chloride) so that alginate material precipitates in the form of the insoluble calcium salt.
- calcium ions usually provided by calcium chloride
- the alginates are highly hydrophilic and have thus found particular use in the dressing of "highly exuding" wounds where this absorbing allows comparatively large quantities of exudate to be absorbed before the alginate material dissolves.
- an alginate material which comprises of zinc, copper, silver, cerium, manganese, or cobalt cations and/or any cation which is an enzyme co-factor, save that the cation is not solely calcium, sodium or a mixture of these two cations.
- Enzyme co-factors include Mg 2+ , Co 2+ , Mn + and Fe 3+ ions.
- the cation (or mixture of abovementioned cations) provide exchangeable ions which have useful wound healing properties and the alginate serves as a base material for the delivery of these cations to the wound site.
- the absorbency of the alginate material is an added advantage.
- the minimum amount of the cation incorporated in the alginate material is preferably (l/2n) moles (of cation) per mole of sugar residue in the alginate.
- the minimum amount is preferably 0.25 moles.
- the preferred minimum amount is 0.5 moles (of cation).
- the preferred maximum amount for the cation is (1/n) moles per mole of sugar residue in the alginate.
- alginate materials of the invention may be used in a wide range of wound healing applications.
- One particular application is for the treatment of leg ulcers which might contain in excess of 10 5 organisms/ml.
- an alginate material containing copper ions may initially be applied to the ulcer and would cause the wound to flush itself.
- a further alginate material containing zinc ions may be applied to the ulcer to promote wound healing.
- the alginate material may be in the form of a porous membrane but is more preferably in the form of a porous fibrous material or of a particulate material of sufficiently small size for formulation into an aerosol (which may then be sprayed onto a wound) .
- a porous fibrous material produced, for example, as described below is particulary advantageous because of the high internal surface are avoidable for ion-exchange.
- Such a fibrous material may be produced by spinning a solution of a soluble alginate (particularly sodium or magnesium alginate) into bath containing the cations to be incorporated in the final alginate material.
- the solution may, for example, be spun into a bath by dissolving the chloride or nitrate of zinc and/or silver in water.
- Such fibrous materials may be supported in ' any suitable way for application to a wound site.
- the support may, for example, comprise a porous textile dressing or a porous membrane or a porous polymeric membrane comprised of a hydrophobic polymer defining a porous (particularly microporous) structure and a hydrophilic polymer provided at the surfaces, including the internal pore surfaces, of the hydrophobic polymer.
- a membrane is disclosed in WO-A-90/11820 (Beam Tech) .
- Particulate alginate material for formulation into an aerosol
- Particulate alginate material may be produced by subjecting particulate calcium alginate material to an ion exchange process with the appropriate cation(s).
- An alginate membrane may be produced by preparing an aqueous solution of a soluble alginate material, forming the solution into the shape of a membrane, and treating the thus formed membrane precursor with a liquid containing cations which precipitate alginate material from solution as a porous membrane.
- the precipitation bath may be aqueous or may be or include a water miscible organic solvent (e.g. DMSO, DMF).
- a water miscible organic solvent e.g. DMSO, DMF.
Landscapes
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
An alginate material useful particularly as a wound dressing incorporates cations selected from zinc, copper, silver, cerium, manganese, cobalt, or any cation which is an enzyme cofactor, save that the cation is not solely calcium, sodium or a mixture of these two cations.
Description
ALGINATE MATERIALS
The present invention relates alginate materials which are useful particularly (but not exclusively) for wound dressings.
It is known that alginate materials have haemostatic and wound healing properties and may be used in various types of wound dressing* (see for example EP-A- 0 236 104 (Courtauldε) ) .
Conventionally, alginates for wound dressings are prepared by spinning a solution of sodium alginate into a' bath containing calcium ions (usually provided by calcium chloride) so that alginate material precipitates in the form of the insoluble calcium salt. For certain applications, it may be desirable for the alginate to have a greater degree of solubility in body fluids, in which case the calcium alginate may be treated in a bath of sodium ions so that some of the calcium is replaced by sodium to provide a more soluble form.
The alginates are highly hydrophilic and have thus found particular use in the dressing of "highly exuding" wounds where this absorbing allows comparatively large quantities of exudate to be absorbed before the alginate material dissolves.
It is a object of the present invention to provide alginate materials with improved properties for the treatment of wounds.
According to the present invention there is provide an alginate material which comprises of zinc, copper, silver, cerium, manganese, or cobalt cations and/or any cation which is an enzyme co-factor, save that the cation is not solely calcium, sodium or a mixture of these two cations. Enzyme co-factors include Mg2+, Co2+, Mn + and Fe3+ ions.
In the alginate material of the invention, the cation (or mixture of abovementioned cations) provide exchangeable
ions which have useful wound healing properties and the alginate serves as a base material for the delivery of these cations to the wound site. The absorbency of the alginate material is an added advantage.
Assuming that the cation has an oxidation slate of n+ the minimum amount of the cation incorporated in the alginate material is preferably (l/2n) moles (of cation) per mole of sugar residue in the alginate. Thus, for a divalent ion (n=2) the minimum amount is preferably 0.25 moles. Similarly for a monovalent ion (n=l) the preferred minimum amount is 0.5 moles (of cation). The preferred maximum amount for the cation is (1/n) moles per mole of sugar residue in the alginate. Thus the preferred maximum for divalent cation (n=2) is 0.5 moles.
The ions shown below have the indicated properties:
Ion Wound Healing Property
Zn2+ promotes healing
Ag+ bactericidal action
Cu2+ anti-microbial, wound flushing
Ce + anti-immunosuppressant
Mn2+ enzyme (oxidase) co-factor
Co + enzyme co-factor
It will thus be appreciated that alginate materials of the invention may be used in a wide range of wound healing applications. One particular application is for the treatment of leg ulcers which might contain in excess of 105 organisms/ml. In this case, an alginate material containing copper ions may initially be applied to the ulcer and would cause the wound to flush itself. Subsequently, a further alginate material containing zinc ions may be applied to the ulcer to promote wound healing.
In order to assist delivery of the cations into the wound, it is possible to use an iontophoretic technique so as to "drive" the ions into the wound.
The alginate material may be in the form of a porous
membrane but is more preferably in the form of a porous fibrous material or of a particulate material of sufficiently small size for formulation into an aerosol (which may then be sprayed onto a wound) . The use of a porous fibrous material (produced, for example, as described below) is particulary advantageous because of the high internal surface are avoidable for ion-exchange.
Such a fibrous material may be produced by spinning a solution of a soluble alginate (particularly sodium or magnesium alginate) into bath containing the cations to be incorporated in the final alginate material. The solution may, for example, be spun into a bath by dissolving the chloride or nitrate of zinc and/or silver in water.
Such fibrous materials may be supported in 'any suitable way for application to a wound site. The support may, for example, comprise a porous textile dressing or a porous membrane or a porous polymeric membrane comprised of a hydrophobic polymer defining a porous (particularly microporous) structure and a hydrophilic polymer provided at the surfaces, including the internal pore surfaces, of the hydrophobic polymer. Such a membrane is disclosed in WO-A-90/11820 (Beam Tech) .
Particulate alginate material (for formulation into an aerosol) may be produced by subjecting particulate calcium alginate material to an ion exchange process with the appropriate cation(s).
An alginate membrane may be produced by preparing an aqueous solution of a soluble alginate material, forming the solution into the shape of a membrane, and treating the thus formed membrane precursor with a liquid containing cations which precipitate alginate material from solution as a porous membrane.
The precipitation bath may be aqueous or may be or include a water miscible organic solvent (e.g. DMSO, DMF).
Claims
1. An alginate material which incorporates cations selected from zinc, copper, silver, cerium, manganese, cobalt, or any cation which is an enzyme cofactor, save that the cation is not solely calcium, sodium or a mixture of these two cations.
2. A material as claimed in claim 1 including an enzyme cofactor selected from Mg2+, Co2+, Mn2+, and Fe3+.
3. An alginate material as claimed in claim 1 or 2 wherein the alginate material is in the form of a fibre, a membrane, a film, or in the form of particles.
4. An alginate material as claimed in claim 3 wherein the alginate material comprises particles in the form of an aerosol.
5. A wound dressing comprising an alginate material as claimed in any one of claims 1 to 3.
6. A wound dressing as claimed in claim 4 wherein the alginate material is associated with a porous membrane comprised of a hydrophobic polymer defining the porous structure and a hydrophilic polymer provided at the surfaces, including the internal pore surfaces, of the hydrophobic polymer.
7. A method of producing an alginate material as claimed in claim 1 comprising providing a solution of a soluble alginate (preferably sodium or magnesium alginate) in a precipitation bath which contains at least one of said cations.
8. A method as claimed in claim 6 wherein said soluble alginate is spun into the bath to produce a fibre.
9. A method as claimed in claim 6 wherein said solution of the soluble alginate material is formed into the shape of a membrane and introduced into the precipitation bath.
10. A material as claimed in any one of claims 1 to 4 wherein the cation has an oxidation state of n+ and the amount of the cation present in the alginate material is at least (l/2n) moles per mole of sugar residue.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909001878A GB9001878D0 (en) | 1990-01-26 | 1990-01-26 | Alginate materials |
| GB9001878.9 | 1990-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991011206A1 true WO1991011206A1 (en) | 1991-08-08 |
Family
ID=10669992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1991/000119 WO1991011206A1 (en) | 1990-01-26 | 1991-01-28 | Alginate materials |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU7227991A (en) |
| GB (1) | GB9001878D0 (en) |
| WO (1) | WO1991011206A1 (en) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4204012A1 (en) * | 1992-02-12 | 1993-08-19 | Ulrich Prof Dr Zimmermann | MITOGEN-FREE SUBSTANCE, THEIR PRODUCTION AND USE |
| WO1994000164A1 (en) * | 1992-06-29 | 1994-01-06 | C. V. Laboratories Limited | Sustained release alginate fibre and process for the preparation thereof |
| WO1995004078A1 (en) * | 1993-07-30 | 1995-02-09 | University College London | Cell adhesion protein complexes with copper |
| US6372248B1 (en) * | 1994-10-28 | 2002-04-16 | Innovative Technologies Limited | Dehydrated hydrogels |
| EP1252901A1 (en) * | 2001-04-25 | 2002-10-30 | Les Laboratoires Brothier | Powdered wound dressing and method for producing the same |
| EP1153620A3 (en) * | 2000-05-12 | 2003-05-28 | Johnson & Johnson Medical Ltd. | Solid compositions exhibiting selective binding to dissolved iron |
| GB2392913A (en) * | 2002-09-11 | 2004-03-17 | Johnson & Johnson Medical Ltd | Complex of an anionic polysaccharide with silver |
| WO2004024197A1 (en) | 2002-09-11 | 2004-03-25 | Johnson & Johnson Medical Limited | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| WO2004084961A1 (en) * | 2003-03-28 | 2004-10-07 | Coloplast A/S | A wound dressing |
| US6861570B1 (en) | 1997-09-22 | 2005-03-01 | A. Bart Flick | Multilayer conductive appliance having wound healing and analgesic properties |
| US7005556B1 (en) | 1995-09-05 | 2006-02-28 | Argentum Medical | Multilayer wound dressing |
| US7214847B1 (en) | 1997-09-22 | 2007-05-08 | Argentum Medical, L.L.C. | Multilayer conductive appliance having wound healing and analgesic properties |
| US7230153B2 (en) | 1997-09-22 | 2007-06-12 | Argentum International, Llc | Multilayer conductive appliance having wound healing and analgesic properties |
| EP1882482A2 (en) | 2001-09-12 | 2008-01-30 | ConvaTec Limited | Antibacterial wound dressing |
| US7385101B2 (en) | 2001-12-20 | 2008-06-10 | Noble Fiber Technologies, Llc | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same |
| WO2009097672A3 (en) * | 2008-02-08 | 2010-05-20 | Luiz Eduardo Da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
| US8124826B2 (en) | 2003-11-18 | 2012-02-28 | Systagenix Wound Management (Us), Inc. | Antioxidant and antimicrobial wound dressing materials |
| US8507652B2 (en) | 2008-02-08 | 2013-08-13 | Luis Eduardo da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
| US8728513B2 (en) | 2000-09-21 | 2014-05-20 | Convatec Technologies Inc. | Silver containing wound dressing |
| EP1942851B1 (en) | 2005-11-02 | 2016-11-23 | BSN medical GmbH | Absorptive element to be mounted on human or animal skin surfaces |
| WO2018214007A1 (en) | 2017-05-23 | 2018-11-29 | 惠州华阳医疗器械有限公司 | Antibacterial wound dressing and preparation method and application thereof |
| US11061033B2 (en) | 2016-04-05 | 2021-07-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Assay for detection of bladder or prostate cancer |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB629419A (en) * | 1946-12-05 | 1949-09-20 | Johnson & Johnson Great Britai | Improvements in and relating to surgical dressings |
| GB976301A (en) * | 1960-10-27 | 1964-11-25 | Calmic Ltd | Preparation and use of alginates |
| GB1255155A (en) * | 1968-10-30 | 1971-12-01 | Wallace Cameron & Company Ltd | Improvements in or relating to preformed surgical or medical dressings |
| GB1328088A (en) * | 1969-09-27 | 1973-08-30 | Wallace Cameron Co Ltd | Solubilized alginic materials |
| EP0243069A2 (en) * | 1986-04-17 | 1987-10-28 | JOHNSON & JOHNSON MEDICAL, INC. | Adhesive wound dressing |
-
1990
- 1990-01-26 GB GB909001878A patent/GB9001878D0/en active Pending
-
1991
- 1991-01-28 WO PCT/GB1991/000119 patent/WO1991011206A1/en unknown
- 1991-01-28 AU AU72279/91A patent/AU7227991A/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB629419A (en) * | 1946-12-05 | 1949-09-20 | Johnson & Johnson Great Britai | Improvements in and relating to surgical dressings |
| GB976301A (en) * | 1960-10-27 | 1964-11-25 | Calmic Ltd | Preparation and use of alginates |
| GB1255155A (en) * | 1968-10-30 | 1971-12-01 | Wallace Cameron & Company Ltd | Improvements in or relating to preformed surgical or medical dressings |
| GB1328088A (en) * | 1969-09-27 | 1973-08-30 | Wallace Cameron Co Ltd | Solubilized alginic materials |
| EP0243069A2 (en) * | 1986-04-17 | 1987-10-28 | JOHNSON & JOHNSON MEDICAL, INC. | Adhesive wound dressing |
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4204012A1 (en) * | 1992-02-12 | 1993-08-19 | Ulrich Prof Dr Zimmermann | MITOGEN-FREE SUBSTANCE, THEIR PRODUCTION AND USE |
| WO1994000164A1 (en) * | 1992-06-29 | 1994-01-06 | C. V. Laboratories Limited | Sustained release alginate fibre and process for the preparation thereof |
| US5690955A (en) * | 1992-06-29 | 1997-11-25 | E. R. Squibb & Sons, Inc. | Sustained release alginate fibre and process for the preparation thereof |
| WO1995004078A1 (en) * | 1993-07-30 | 1995-02-09 | University College London | Cell adhesion protein complexes with copper |
| US5798116A (en) * | 1993-07-30 | 1998-08-25 | University College London | Stabilized materials comprised of copper ion-containing fibronectin mats |
| US6372248B1 (en) * | 1994-10-28 | 2002-04-16 | Innovative Technologies Limited | Dehydrated hydrogels |
| US7005556B1 (en) | 1995-09-05 | 2006-02-28 | Argentum Medical | Multilayer wound dressing |
| US7230153B2 (en) | 1997-09-22 | 2007-06-12 | Argentum International, Llc | Multilayer conductive appliance having wound healing and analgesic properties |
| US7214847B1 (en) | 1997-09-22 | 2007-05-08 | Argentum Medical, L.L.C. | Multilayer conductive appliance having wound healing and analgesic properties |
| US7291762B2 (en) | 1997-09-22 | 2007-11-06 | Argentum International, Llc | Multilayer conductive appliance having wound healing and analgesic properties |
| US6861570B1 (en) | 1997-09-22 | 2005-03-01 | A. Bart Flick | Multilayer conductive appliance having wound healing and analgesic properties |
| EP1153620A3 (en) * | 2000-05-12 | 2003-05-28 | Johnson & Johnson Medical Ltd. | Solid compositions exhibiting selective binding to dissolved iron |
| US10010647B2 (en) | 2000-09-21 | 2018-07-03 | Convatec Technologies Inc. | Silver containing wound dressing |
| US9345805B2 (en) | 2000-09-21 | 2016-05-24 | Convatec Technologies Inc. | Silver containing wound dressing |
| US10391197B2 (en) | 2000-09-21 | 2019-08-27 | Convatec Technologies Inc. | Silver containing wound dressing |
| US8728513B2 (en) | 2000-09-21 | 2014-05-20 | Convatec Technologies Inc. | Silver containing wound dressing |
| US9066989B2 (en) | 2000-09-21 | 2015-06-30 | Convatec Technologies Inc. | Silver containing wound dressing |
| EP1252901A1 (en) * | 2001-04-25 | 2002-10-30 | Les Laboratoires Brothier | Powdered wound dressing and method for producing the same |
| US10342890B2 (en) | 2001-09-12 | 2019-07-09 | Convatec Limited | Antibacterial wound dressing |
| EP1882482A2 (en) | 2001-09-12 | 2008-01-30 | ConvaTec Limited | Antibacterial wound dressing |
| US8828424B2 (en) | 2001-09-12 | 2014-09-09 | Convatec Limited | Antibacterial wound dressing |
| US7385101B2 (en) | 2001-12-20 | 2008-06-10 | Noble Fiber Technologies, Llc | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same |
| GB2392913A (en) * | 2002-09-11 | 2004-03-17 | Johnson & Johnson Medical Ltd | Complex of an anionic polysaccharide with silver |
| WO2004024197A1 (en) | 2002-09-11 | 2004-03-25 | Johnson & Johnson Medical Limited | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| US8461410B2 (en) | 2002-09-11 | 2013-06-11 | Ethicon, Inc. | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| GB2392913B (en) * | 2002-09-11 | 2007-04-04 | Johnson & Johnson Medical Ltd | Wound dressings comprising complexes of oxidised celluloses with silver |
| WO2004084961A1 (en) * | 2003-03-28 | 2004-10-07 | Coloplast A/S | A wound dressing |
| US8124826B2 (en) | 2003-11-18 | 2012-02-28 | Systagenix Wound Management (Us), Inc. | Antioxidant and antimicrobial wound dressing materials |
| US10143771B2 (en) | 2003-11-18 | 2018-12-04 | Kci Usa, Inc. | Antioxidant and antimicrobial wound dressing materials |
| US10327955B2 (en) | 2005-11-02 | 2019-06-25 | Bsn Medical Gmbh | Absorbent article for application to human or animal skin surfaces |
| EP2359784B1 (en) | 2005-11-02 | 2017-09-27 | BSN medical GmbH | Absorption body for attachment to human or animal skin surfaces |
| EP1942851B1 (en) | 2005-11-02 | 2016-11-23 | BSN medical GmbH | Absorptive element to be mounted on human or animal skin surfaces |
| US10166147B2 (en) | 2005-11-02 | 2019-01-01 | Bsn Medical Gmbh | Absorbent article for application to human or animal skin surfaces |
| WO2009097672A3 (en) * | 2008-02-08 | 2010-05-20 | Luiz Eduardo Da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
| JP2011511013A (en) * | 2008-02-08 | 2011-04-07 | エデュアルド ダ クルス，ルイス | Pharmaceutical compositions, dressings and methods for treating skin lesions, intermediate compositions and processes for preparing the dressings, and use of cerium salts in combination with a collagen matrix |
| US8507652B2 (en) | 2008-02-08 | 2013-08-13 | Luis Eduardo da Cruz | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
| US11061033B2 (en) | 2016-04-05 | 2021-07-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Assay for detection of bladder or prostate cancer |
| WO2018214007A1 (en) | 2017-05-23 | 2018-11-29 | 惠州华阳医疗器械有限公司 | Antibacterial wound dressing and preparation method and application thereof |
| US11129847B2 (en) | 2017-05-23 | 2021-09-28 | Huizhou Foryou Medical Devices Co., Ltd. | Antibacterial wound dressing, method for preparing the same, and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9001878D0 (en) | 1990-03-28 |
| AU7227991A (en) | 1991-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1991011206A1 (en) | Alginate materials | |
| DE4026153C2 (en) | ||
| EP1539070B1 (en) | Antimicrobial, silver-containing wound dressing for continuous release | |
| EP1523997B1 (en) | Foam dressing comprising an antimicrobial silver | |
| CN100394986C (en) | Wound dressing containing Ag-Zn composition | |
| KR101377569B1 (en) | Antimicrobial Wound Dressing and Preparing Method of the Same | |
| EP0901382B1 (en) | Reinforced hydrogels | |
| PL207044B1 (en) | Wound dressing materials comprising complexes of anionic polysaccharides with silver | |
| KR101865781B1 (en) | Hydrogel comprising oxidized polysaccharide and amine-modified hyaluronic acid for wound dressings and manufacturing method thereof | |
| CN1568191A (en) | Light stabilized antimicrobial materials | |
| KR102264090B1 (en) | Antimicrobial hydrogel with metal organic frameworks | |
| JP4808402B2 (en) | Wound dressing material containing a complex of anionic polysaccharide and silver | |
| JPH10140472A (en) | Antimicrobial fibers, antimicrobial filter material, and methods for producing them | |
| EP0165074B1 (en) | Absorbent polymer material and its preparation | |
| JP3999823B2 (en) | Cross-linked polysaccharide, process for producing the same and composite material thereby | |
| EP1044694A1 (en) | Polymeric material for artificial bone | |
| US20200306289A1 (en) | Wound healing topical formulation and preparation thereof | |
| EP4134107A1 (en) | Wound dressing comprising a hydrogel layer and a wound contact layer comprising hyaluronic acid | |
| JP2919516B2 (en) | Artificial skin and method for producing the same | |
| KR20010001271A (en) | Antibacterial agent based on Ag-alginate to be used for fiber | |
| JPH07155369A (en) | Wound dressing | |
| JPS6244258A (en) | Medical living body surface covering material | |
| JPH08126659A (en) | Base material for medical care containing antifungal material and wound covering material | |
| CN115401959A (en) | Hydroxyapatite fiber/gelatin double-layer antibacterial film capable of guiding bone regeneration and preparation method thereof | |
| HU200092B (en) | Process for production of dextrane perle-polimers for poudre for wounds suitable for improvement of its medical utilization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |